08/18/2011

Intronix Technologies Corporation

Myoguide ™  Injection Site Targeting System Earns CE Mark

Myoguide Earns a CE mark
Myoguide poised to become essential pain and spasticity treatment tool in hands of European physicians 

June 16, 2011- Clinicians throughout the European Union may now treat their patients suffering from acute and chronic pain, or spasticity, with a highly portable electromyographic (EMG) precision device. According to clinical studies, use of Myoguide can lead to more accurate injection site targeting, which may also enhance treatment of pain and spasticity, and improve the outcomes of treatment.

Early work on tenderness and motor points described the beginning of an important new medical subject “neuropathic pain”. Electromyographic (EMG) evidence of neuropathy in the nerves, tender muscles, increased insertion activity, polyphasic action potentials, prolonged motor action potentials, etc., demonstrated this. Pain can be of muscular origin as well. This can be due to damaged muscle fibers leading to spasm and what can be termed as “myofascial pain”.

The newly approved Myoguide battery-powered handheld provides superior injection site targeting through its ability to detect and display the EMG signals characteristically emitted by these hidden pain sources. Clinicians can see and hear EMG activity. Treatment delivery can be in the form of neuromodulator injections, such as Botox©, Dysport©, and Xeomin©, or as simple as inserting a dry needle electrode.

Myoguide provides both quantitative and qualitative feedback necessary for clinicians to make decisions about treatment and treatment delivery. All these features are wrapped up in a small , battery operated, hand-held device:

Myoguide helps identify involved muscles through pre-injection, or pre-intervention evaluation. This can be done by either EMG evaluation, or stimulation location, and is particularly useful in cases where the site may be surrounded by essential nerves and blood vessels

Pre-injection evaluation can lead to use of reduced drug dose and volume, thereby contributing to limiting drug diffusion into adjacent areas. This is especially pertinent in cases where drugs will be re-injected on follow up appointments, as the basal EMG activity level can be assessed before a dose decision is finalized.


About Intronix Technologies:
Intronix is a Canadian company, manufacturing medical devices since 1984, and for other companies, as an original equipment manufacturer (OEM), since 1989. Intronix designs and produces innovative electromyographic (EMG) systems for applications in the diagnosis and management of musculoskeletal pain, spasticity, and fibromyalgia. For more information, visit www.intronixtech.com for a wealth of information on Myoguide, including clinical video demonstrations. Contact: info@intronixtech.com